Schrodinger (NASDAQ:SDGR) Sets New 1-Year High – Time to Buy?

Schrodinger, Inc. (NASDAQ:SDGR) shares hit a new 52-week high during mid-day trading on Monday . The company traded as high as $30.62 and last traded at $30.3950, with a volume of 1082149 shares traded. The stock had previously closed at $29.02.

Analyst Ratings Changes

SDGR has been the topic of several analyst reports. Wall Street Zen raised shares of Schrodinger from a “strong sell” rating to a “hold” rating in a report on Saturday, August 8th. UBS Group initiated coverage on shares of Schrodinger in a research note on Friday, August 14th. They set a “neutral” rating and a $19.00 price objective on the stock. Finally, Weiss Ratings raised shares of Schrodinger from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, August 27th. Three equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $20.50.

Schrodinger Stock Performance

The company’s 50-day moving average is $19.08 and its 200-day moving average is $15.45. The firm has a market cap of $2.27 billion, a price-to-earnings ratio of -41.49 and a beta of 1.69.

Schrodinger (NASDAQ:SDGR) last announced its earnings results on Wednesday, August 5th. The company reported $0.08 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.41) by $0.49. Schrodinger had a negative net margin of 20.98% and a negative return on equity of 16.37%. The company had revenue of $58.89 million during the quarter, compared to the consensus estimate of $47.19 million. During the same period in the previous year, the firm posted ($0.65) earnings per share. The company’s revenue was up 7.5% on a year-over-year basis. On average, analysts predict that Schrodinger, Inc. will post -1.5 EPS for the current year.

Insider Buying and Selling at Schrodinger

In other news, insider Karen Akinsanya sold 31,599 shares of the company’s stock in a transaction on Thursday, September 17th. The stock was sold at an average price of $29.37, for a total transaction of $928,062.63. Following the transaction, the insider owned 69,956 shares of the company’s stock, valued at $2,054,607.72. This represents a 31.12% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 10.10% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. EverSource Wealth Advisors LLC lifted its holdings in Schrodinger by 722.8% in the fourth quarter. EverSource Wealth Advisors LLC now owns 1,374 shares of the company’s stock valued at $25,000 after buying an additional 1,207 shares during the period. Hantz Financial Services Inc. grew its holdings in Schrodinger by 5,025.8% during the 4th quarter. Hantz Financial Services Inc. now owns 1,589 shares of the company’s stock worth $28,000 after acquiring an additional 1,558 shares during the period. Purpose Unlimited Inc. acquired a new stake in Schrodinger during the 4th quarter worth $47,000. Allworth Financial LP bought a new stake in shares of Schrodinger during the 2nd quarter valued at $86,000. Finally, Integrated Wealth Concepts LLC acquired a new position in shares of Schrodinger in the 2nd quarter valued at $102,000. 79.05% of the stock is currently owned by institutional investors and hedge funds.

About Schrodinger

Schrödinger, Inc develops computational software designed to accelerate drug discovery and materials science research. Its platform uses physics-based modeling, machine learning and related computational methods to help scientists analyze molecular structures, predict interactions and identify potential compounds for further development.

The company’s software products support a range of research activities, including molecular modeling, virtual screening, structure-based drug design, free-energy calculations and collaborative data management.